Madrigal reports new safety data for NASH candidate resmetirom weeks ahead of PDUFA date
08 Feb 2024
Madrigal has lifted the curtain on additional late-stage safety results for its nonalcoholic steatohepatitis (NASH) drug resmetirom, with analysts expressing overall optimism on the looming FDA approval decision.
On the candidate’s safety, resmetirom’s mechanism meant it could theoretically suppress the secretion of pituitary thyrotropin, which could in turn “promote a hypothyroid state in tissues not targeted by the agent,” Kenneth Cusi, chief of endocrinology, diabetes and metabolism at the University of Florida, said in an editorial published on the in the New England Journal of Medicine. Resmetirom is a thyroid hormone receptor-beta agonistthyroid hormone receptor-beta agonist.
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.